{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:39:34Z","timestamp":1792528774096,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08428-9","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:34:23Z","timestamp":1784824463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of non-hormonal pharmacotherapies for depressive and anxiety symptoms during the menopausal transition and postmenopause: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"given":"Mojtaba","family":"Hedayati Ch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Bostani Khalesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Abedinzade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"10","key":"8428_CR1","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/GME.0000000000001424","volume":"26","author":"SR El Khoudary","year":"2019","unstructured":"El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women\u2019s health at midlife: a progress report from the Study of Women\u2019s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213\u201327. https:\/\/doi.org\/10.1097\/GME.0000000000001424.","journal-title":"Menopause"},{"issue":"3","key":"8428_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ogc.2011.05.006","volume":"38","author":"RC Thurston","year":"2011","unstructured":"Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women\u2019s Health across the Nation. Obstet Gynecol Clin North Am. 2011;38(3):489\u2013501. https:\/\/doi.org\/10.1016\/j.ogc.2011.05.006.","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"2","key":"8428_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/10398562231165439","volume":"31","author":"S Alblooshi","year":"2023","unstructured":"Alblooshi S, Taylor M, Gill N. Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review. Australas Psychiatry. 2023;31(2):165\u201373. https:\/\/doi.org\/10.1177\/10398562231165439.","journal-title":"Australas Psychiatry"},{"key":"8428_CR4","doi-asserted-by":"publisher","first-page":"1071232","DOI":"10.3389\/fpsyg.2023.1071232","volume":"14","author":"J Peng","year":"2023","unstructured":"Peng J, Zhang J, Wang B, et al. The relationship between sleep quality and occupational well-being in employees: The mediating role of occupational self-efficacy. Front Psychol. 2023;14:1071232. https:\/\/doi.org\/10.3389\/fpsyg.2023.1071232.","journal-title":"Front Psychol"},{"key":"8428_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.genhosppsych.2026.03.010","volume":"100","author":"I Balasubramanian","year":"2026","unstructured":"Balasubramanian I, Abhijita B, Krishnamoorthy Y, Gnanadhas J, Beg MJ, Menon V. Prevalence and incidence of depressive, anxiety, and insomnia symptoms in perimenopausal and postmenopausal women: Systematic review and meta-analysis. Gen Hosp Psychiatry. 2026;100:325\u201335. https:\/\/doi.org\/10.1016\/j.genhosppsych.2026.03.010.","journal-title":"Gen Hosp Psychiatry"},{"key":"8428_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2147\/IJWH.S491640","volume":"17","author":"CJ Gibson","year":"2025","unstructured":"Gibson CJ, Ajmera M, O\u2019Sullivan F, et al. A Systematic Review of Anxiety and Depressive Symptoms Among Women Experiencing Vasomotor Symptoms Across Reproductive Stages in the US. Int J Womens Health. 2025;17:537\u201352. https:\/\/doi.org\/10.2147\/IJWH.S491640.","journal-title":"Int J Womens Health"},{"issue":"9","key":"8428_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3390\/brainsci15091003","volume":"15","author":"JM Cho","year":"2025","unstructured":"Cho JM, Lee J, Ahn EM, Bae J. Beyond Hot Flashes: The Role of Estrogen Receptors in Menopausal Mental Health and Cognitive Decline. Brain Sci. 2025;15(9):1003. https:\/\/doi.org\/10.3390\/brainsci15091003.","journal-title":"Brain Sci"},{"issue":"7","key":"8428_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/jamapsychiatry.2015.0111","volume":"72","author":"PJ Schmidt","year":"2015","unstructured":"Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of Estradiol Withdrawal on Mood in Women with Past Perimenopausal Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(7):714\u201326. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0111.","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"8428_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/GME.0000000000000323","volume":"22","author":"E Toffol","year":"2015","unstructured":"Toffol E, Heikinheimo O, Partonen T. Hormone therapy and mood in perimenopausal and postmenopausal women: a narrative review. Menopause. 2015;22(5):564\u201378. https:\/\/doi.org\/10.1097\/GME.0000000000000323.","journal-title":"Menopause"},{"issue":"5","key":"8428_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1192\/bjp.2025.101","volume":"228","author":"S Glynne","year":"2026","unstructured":"Glynne S, Kamal A, McColl L, et al. Transdermal oestradiol and testosterone therapy for menopausal depression and mood symptoms: retrospective cohort study. Br J Psychiatry. 2026;228(5):409\u201318. https:\/\/doi.org\/10.1192\/bjp.2025.101.","journal-title":"Br J Psychiatry"},{"key":"8428_CR11","doi-asserted-by":"publisher","first-page":"564781","DOI":"10.3389\/fendo.2021.564781","volume":"12","author":"J Mehta","year":"2021","unstructured":"Mehta J, Kling JM, Manson JE. Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. Front Endocrinol (Lausanne). 2021;12:564781. https:\/\/doi.org\/10.3389\/fendo.2021.564781.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"8428_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/GCO.0000000000001009","volume":"37","author":"AJ Voedisch","year":"2025","unstructured":"Voedisch AJ. Updates in nonhormonal therapy for perimenopausal and menopausal symptoms. Curr Opin Obstet Gynecol. 2025;37(2):67\u201374. https:\/\/doi.org\/10.1097\/GCO.0000000000001009.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1","key":"8428_CR13","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.1038\/s41598-020-64910-8","volume":"10","author":"CK Wu","year":"2020","unstructured":"Wu CK, Tseng PT, Wu MK, et al. Antidepressants during and after Menopausal Transition: A Systematic Review and Meta-Analysis. Sci Rep. 2020;10(1):8026. https:\/\/doi.org\/10.1038\/s41598-020-64910-8.","journal-title":"Sci Rep"},{"key":"8428_CR14","doi-asserted-by":"publisher","first-page":"108096","DOI":"10.1016\/j.maturitas.2024.108096","volume":"189","author":"S Kingsberg","year":"2024","unstructured":"Kingsberg S, Banks V, Caetano C, et al. Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study. Maturitas. 2024;189:108096. https:\/\/doi.org\/10.1016\/j.maturitas.2024.108096.","journal-title":"Maturitas"},{"issue":"24","key":"8428_CR15","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.3390\/healthcare13243206","volume":"13","author":"JH Kim","year":"2025","unstructured":"Kim JH, Yu HJ. Nonpharmacological Intervention Effects on Middle-Aged Women with Menopausal Symptoms: A Systematic Review and Meta-Analysis. Healthc (Basel). 2025;13(24):3206. https:\/\/doi.org\/10.3390\/healthcare13243206.","journal-title":"Healthc (Basel)"},{"issue":"4","key":"8428_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1139\/jpn.0831","volume":"33","author":"CN Soares","year":"2008","unstructured":"Soares CN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J Psychiatry Neurosci. 2008;33(4):331\u201343.","journal-title":"J Psychiatry Neurosci"},{"issue":"2","key":"8428_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/104012370902100202","volume":"21","author":"R Defronzo Dobkin","year":"2009","unstructured":"Defronzo Dobkin R, Menza M, Allen LA, et al. Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study. Ann Clin Psychiatry. 2009;21(2):70\u20136.","journal-title":"Ann Clin Psychiatry"},{"issue":"3","key":"8428_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.2010.2016","volume":"305","author":"EW Freeman","year":"2011","unstructured":"Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305(3):267\u201374. https:\/\/doi.org\/10.1001\/jama.2010.2016.","journal-title":"JAMA"},{"issue":"21","key":"8428_CR19","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1001\/jama.289.21.2827","volume":"289","author":"V Stearns","year":"2003","unstructured":"Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289(21):2827\u201334. https:\/\/doi.org\/10.1001\/jama.289.21.2827.","journal-title":"JAMA"},{"issue":"1","key":"8428_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00042192-200512010-00006","volume":"12","author":"E Suvanto-Luukkonen","year":"2005","unstructured":"Suvanto-Luukkonen E, Koivunen R, Sundstr\u00f6m H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause. 2005;12(1):18\u201326. https:\/\/doi.org\/10.1097\/00042192-200512010-00006","journal-title":"Menopause"},{"issue":"3","key":"8428_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/01.gme.0000191309.75606.c7","volume":"13","author":"CN Soares","year":"2006","unstructured":"Soares CN, Arsenio H, Joffe H, et al. Paroxetine controlled release for the treatment of vasomotor symptoms in menopausal women: a randomized controlled trial. Menopause. 2006;13(3):403\u201312. https:\/\/doi.org\/10.1097\/01.gme.0000191309.75606.c7.","journal-title":"Menopause"},{"issue":"4","key":"8428_CR22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/01.AOG.0000258567.64152.d3","volume":"109","author":"D Grady","year":"2007","unstructured":"Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flashes: a randomized controlled trial. Obstet Gynecol. 2007;109(4):823\u201330. https:\/\/doi.org\/10.1097\/01.AOG.0000258567.64152.d3.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"8428_CR23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/01.gme.0000247014.43066.c5","volume":"14","author":"M Kalay","year":"2007","unstructured":"Kalay M, Ozkaya M, Sari F, G\u00fcrdal S, G\u00fcltekin M, Zeyneloglu HB. Citalopram in the treatment of climacteric symptoms: a placebo-controlled, randomized trial. Menopause. 2007;14(3):498\u2013503. https:\/\/doi.org\/10.1097\/01.gme.0000247014.43066.c5.","journal-title":"Menopause"},{"issue":"6","key":"8428_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/GME.0b013e31827f77e2","volume":"20","author":"JV Pinkerton","year":"2013","unstructured":"Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M, Bouchard C. Paroxetine 7.5\u00a0mg for menopausal vasomotor symptoms: a 24-week randomized controlled trial. Menopause. 2013;20(6):615\u201324. https:\/\/doi.org\/10.1097\/GME.0b013e31827f77e2.","journal-title":"Menopause"},{"issue":"10","key":"8428_CR25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/GME.0b013e3182a66aa7","volume":"20","author":"JA Simon","year":"2013","unstructured":"Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5\u00a0mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20(10):1027\u201335. https:\/\/doi.org\/10.1097\/GME.0b013e3182a66aa7.","journal-title":"Menopause"},{"issue":"3","key":"8428_CR26","first-page":"542","volume":"28","author":"N Zareen","year":"2016","unstructured":"Zareen N, Ahmed S, Khan A, Javed H, Naeem M, Khan M. Efficacy and tolerability of paroxetine in the management of hot flashes in postmenopausal women. J Ayub Med Coll Abbottabad. 2016;28(3):542\u20136.","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"8","key":"8428_CR27","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4088\/JCP.10m06018blu","volume":"71","author":"SG Kornstein","year":"2010","unstructured":"Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010;71(8):1088\u201396. https:\/\/doi.org\/10.4088\/JCP.10m06018blu.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"8428_CR28","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.4088\/JCP.12m08065","volume":"74","author":"AH Clayton","year":"2013","unstructured":"Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50\u00a0mg\/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013;74(10):1010\u20137. https:\/\/doi.org\/10.4088\/JCP.12m08065.","journal-title":"J Clin Psychiatry"},{"key":"8428_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41398-018-0172-0","volume":"8","author":"J Kulkarni","year":"2018","unstructured":"Kulkarni J, Gavrilidis E, Hudaib AR, Bleeker C, Worsley R, Gurvich C. Development and validation of a new rating scale for perimenopausal depression the Meno-D. Transl Psychiatry. 2018;8:123. https:\/\/doi.org\/10.1038\/s41398-018-0172-0.","journal-title":"Transl Psychiatry"},{"key":"8428_CR30","doi-asserted-by":"publisher","unstructured":"Clayton AH, Kornstein SG, Dunlop BW, Focht K, Musgnung J, Ramey T, et al. Efficacy and safety of desvenlafaxine 50 mg\/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013;74(10):1010-7. https:\/\/doi.org\/10.4088\/JCP.12m08065. PMID: 24229754.","DOI":"10.4088\/JCP.12m08065"},{"issue":"6","key":"8428_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/GME.0000000000000364","volume":"22","author":"B Caan","year":"2015","unstructured":"Caan B, LaCroix AZ, Joffe H, Guthrie KA, Larson JC, Carpenter JS, Cohen LS, Freeman EW, Manson JE, Newton K, Reed S, Rexrode K, Shifren J, Sternfeld B, Ensrud K. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause. 2015;22(6):607\u201315. PMID: 25405571; PMCID: PMC4610378. https:\/\/doi.org\/10.1097\/GME.0000000000000364","journal-title":"Menopause"},{"key":"8428_CR32","doi-asserted-by":"publisher","unstructured":"Mahajan SS, Arora M, Tandon VR, Mahajan A, Kotwal S. Improvement in quality of life of postmenopausal women with depression with commonly used antidepressants (escitalopram vs. desvenlafaxine): a randomized controlled trial in a tertiary care teaching hospital of North India. J Midlife Health. 2022;13(1):80-4. https:\/\/doi.org\/10.4103\/jmh.jmh-150-21. Epub 2022 May 2. PMID: 35707303; PMCID: PMC9190965.","DOI":"10.4103\/jmh.jmh-150-21"},{"issue":"5","key":"8428_CR33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00404-015-3900-1","volume":"293","author":"F Davari-Tanha","year":"2016","unstructured":"Davari-Tanha F, Soleymani-Farsani M, Asadi M, Shariat M, Shirazi M, Hadizadeh H. Comparison of citalopram and venlafaxine\u2019s role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. Arch Gynecol Obstet. 2016;293(5):1007\u201313. https:\/\/doi.org\/10.1007\/s00404-015-3900-1 . Epub 2015 Oct 5. PMID: 26437957.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"8428_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/gme.0b013e31819637b1","volume":"16","author":"DF Archer","year":"2009","unstructured":"Archer DF, Dupont CM, Constantine G, et al. Desvenlafaxine in the treatment of vasomotor symptoms in postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause. 2009;16(4):637\u201344. https:\/\/doi.org\/10.1097\/gme.0b013e31819637b1","journal-title":"Menopause"},{"issue":"5","key":"8428_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/gme.0b013e3181f9a39f","volume":"18","author":"DF Archer","year":"2011","unstructured":"Archer DF, Gass M, Constantine G, et al. Desvenlafaxine for the treatment of vasomotor symptoms in postmenopausal women: a randomized, double-blind, placebo-controlled study. Menopause. 2011;18(5):489\u201396. https:\/\/doi.org\/10.1097\/gme.0b013e3181f9a39f.","journal-title":"Menopause"},{"issue":"10","key":"8428_CR36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/gme.0b013e318256b0cf","volume":"19","author":"JV Pinkerton","year":"2012","unstructured":"Pinkerton JV, Constantine G, Hwang E, et al. Desvenlafaxine for the treatment of vasomotor symptoms in postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause. 2012;19(10):1089\u201396. https:\/\/doi.org\/10.1097\/gme.0b013e318256b0cf.","journal-title":"Menopause"},{"issue":"5","key":"8428_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/GME.0b013e318275f6f1","volume":"20","author":"C Bouchard","year":"2013","unstructured":"Bouchard C, Constantine G, Gass M, et al. Desvenlafaxine and tibolone in the treatment of vasomotor symptoms in postmenopausal women: a randomized, placebo-controlled trial. Menopause. 2013;20(5):477\u201386. https:\/\/doi.org\/10.1097\/GME.0b013e318275f6f1.","journal-title":"Menopause"},{"key":"8428_CR38","doi-asserted-by":"publisher","unstructured":"Cheng RJ, Dupont C, Archer DF, Bao W, Racketa J, Constantine G, et al. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric. 2013;16(1):17-27. https:\/\/doi.org\/10.3109\/13697137.2012.672495.\u00a0Epub 2012 May 31. PMID: 22646219.","DOI":"10.3109\/13697137.2012.672495"},{"issue":"9","key":"8428_CR39","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","volume":"62","author":"K Rickels","year":"2005","unstructured":"Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62(9):1022\u201330. https:\/\/doi.org\/10.1001\/archpsyc.62.9.1022.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"8428_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s0029-7844(02)02712-6","volume":"101","author":"T Guttuso Jr","year":"2003","unstructured":"Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin\u2019s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101(2):337\u201345. https:\/\/doi.org\/10.1016\/s0029-7844(02)02712-6","journal-title":"Obstet Gynecol"},{"issue":"2","key":"8428_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/gme.0b013e3180dca175","volume":"15","author":"DA Butt","year":"2008","unstructured":"Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008;15(2):310\u20138. https:\/\/doi.org\/10.1097\/gme.0b013e3180dca175.","journal-title":"Menopause"},{"issue":"12","key":"8428_CR42","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1097\/GME.0000000000001621","volume":"27","author":"N Santoro","year":"2020","unstructured":"Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020;27(12):1350\u20136. https:\/\/doi.org\/10.1097\/GME.0000000000001621.","journal-title":"Menopause"},{"issue":"10382","key":"8428_CR43","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","volume":"401","author":"S Lederman","year":"2023","unstructured":"Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091\u2013102.","journal-title":"Lancet"},{"issue":"3","key":"8428_CR44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1515\/jcim-2014-0058","volume":"12","author":"G Amin","year":"2015","unstructured":"Amin G, Ashtiyani SC, Kianmehr M, et al. Comparison of a combined herbal product with citalopram in the treatment of menopausal symptoms: a randomized controlled trial. J Complement Integr Med. 2015;12(3):239\u201344. https:\/\/doi.org\/10.1515\/jcim-2014-0058.","journal-title":"J Complement Integr Med"},{"issue":"4","key":"8428_CR45","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ctim.2015.05.006","volume":"23","author":"S Molaie","year":"2015","unstructured":"Molaie S, Jafari A, Khani S, et al. Effect of herbal combination (Nigella sativa and Vitex agnus-castus) with citalopram on menopausal symptoms: a randomized controlled trial. Complement Ther Med. 2015;23(4):533\u20139. https:\/\/doi.org\/10.1016\/j.ctim.2015.05.006","journal-title":"Complement Ther Med"},{"issue":"10","key":"8428_CR46","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1097\/GME.0000000000001174","volume":"25","author":"PM Maki","year":"2018","unstructured":"Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018;25(10):1069\u201385.","journal-title":"Menopause"},{"key":"8428_CR47","volume-title":"Menopausal Symptoms: Comparative Effectiveness of Therapies","author":"MD Grant","year":"2015","unstructured":"Grant MD, Marbella A, Wang AT, et al. Menopausal Symptoms: Comparative Effectiveness of Therapies. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015."},{"key":"8428_CR48","doi-asserted-by":"publisher","first-page":"108087","DOI":"10.1016\/j.maturitas.2024.108087","volume":"188","author":"T Fidecicchi","year":"2024","unstructured":"Fidecicchi T, et al. Neuroendocrine mechanisms of mood disorders during menopause transition: A narrative review. Maturitas. 2024;188:108087.","journal-title":"Maturitas"},{"key":"8428_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s43440-022-00444-2","volume":"75","author":"A B\u0105k","year":"2023","unstructured":"B\u0105k A, et al. Estrogen fluctuations during the menopausal transition are a risk factor for depressive disorders. Pharmacol Rep. 2023;75:32\u201343.","journal-title":"Pharmacol Rep"},{"issue":"9","key":"8428_CR50","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.biopsych.2026.02.002","volume":"99","author":"MD Nathan","year":"2026","unstructured":"Nathan MD, et al. The Impact of Estradiol Dynamics During the Menopause Transition on Depression Risk. Biol Psychiatry. 2026;99(9):779\u201389.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"8428_CR51","doi-asserted-by":"publisher","first-page":"e0153380","DOI":"10.1371\/journal.pone.0153380","volume":"11","author":"R Meister","year":"2016","unstructured":"Meister R, von Wolff A, Mohr H, et al. Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. PLoS ONE. 2016;11(5):e0153380. https:\/\/doi.org\/10.1371\/journal.pone.0153380. Published 2016 May 17.","journal-title":"PLoS ONE"},{"key":"8428_CR52","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41380-021-01386-6","volume":"27","author":"JSW Hong","year":"2022","unstructured":"Hong JSW, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: systematic review, meta-analysis, and rationale. Mol Psychiatry. 2022;27:1339\u201349.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"8428_CR53","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ajog.2019.12.011","volume":"222","author":"D Shan","year":"2020","unstructured":"Shan D, Zou L, Liu X, et al. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;222(6):564\u2013e57912.","journal-title":"Am J Obstet Gynecol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08428-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08428-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08428-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:03:05Z","timestamp":1792526585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08428-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8428"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08428-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable in the manuscript.","order":1,"name":"Ethics","label":"Ethics, consent to participate, and consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"813"}}